Infection risk with JAK inhibitors in dermatoses: a meta-analysis

Patrick A Ireland; Matthew Verheyden; Nicholas Jansson; Deshan Sebaratnam; John Sullivan

doi:10.1111/ijd.17501

Infection risk with JAK inhibitors in dermatoses: a meta-analysis

Int J Dermatol. 2024 Oct 4. doi: 10.1111/ijd.17501. Online ahead of print.

Authors

Patrick A Ireland^{1

2}, Matthew Verheyden^{3

4}, Nicholas Jansson⁵, Deshan Sebaratnam^{2

6}, John Sullivan^{2

7}

Affiliations

¹ Prince of Wales Hospital, Randwick, NSW, Australia.
² University of new South Wales, Randwick, NSW, Australia.
³ University of Sydney, Camperdown, NSW, Australia.
⁴ John Hunter Hospital, Newcastle, NSW, Australia.
⁵ Gold Coast University Hospital, Gold Coast, QLD, Australia.
⁶ Liverpool Hospital, Liverpool, NSW, Australia.
⁷ Kingsway Dermatology and Aesthetics, Miranda, NSW, Australia.

PMID: 39367521
DOI: 10.1111/ijd.17501

Abstract

Evolving evidence suggests that Janus Kinase Inhibitors (JAKi) may predispose to certain infections, including tuberculosis and human herpes viruses. This review aimed to compare the infection risk in patients on a systemic JAKi for a dermatologic indication to a placebo. A systematic review was carried out from inception to June 2023, using the EMBASE, Medline, SCOPUS, and Cochrane Library of Registered Trials databases. Eligible studies included placebo-controlled randomized trials that investigated the incidence of infection in patients with a dermatologic indication. Primary outcomes included the most commonly reported infections pertaining to serious and opportunistic infections, upper respiratory tract infections, nasopharyngitis, herpes simplex, varicella zoster, tuberculosis, neutropenia, and lymphopenia. A meta-analysis of incidence ratios was conducted to determine odds ratios (OR), with a 95% confidence interval (CI) analysis. The meta-analysis found no increased risk of serious (OR: 0.92, 95% CI: 0.61-1.43, P = 0.74) or opportunistic infections (OR: 0.65, 95% CI: 0.32-1.31, P = 0.23). The incidence of varicella-zoster infections was significantly higher in the JAKi cohort (OR: 1.72, 95% CI: 1.08-2.72, P = 0.022). From 25 studies, there was no overall increased risk of herpes simplex infections (OR: 1.43, 95% CI: 0.93-2.23, P = 0.102) to placebo; however, a significantly higher risk in those with atopic dermatitis to alopecia areata was demonstrated (OR: 1.73, 95% CI: 1.13-2.69, P = 0.013). The results of this analysis do not suggest an increased risk of serious and opportunistic infections in those on JAKi compared to placebo. However, they support an increased risk of varicella-zoster infections and a higher risk of herpes simplex infections in those with atopic dermatitis to alopecia areata. The results of this report support these agents' short-term safety but signal that vigilance should be practiced in patients at risk for serious or recurrent herpes virus infections.

Keywords: biologics; infection; medical dermatology; pharmacology; small molecules.

Publication types

Review